The article focuses on the clinical trials designed to study the effects of angiogenesis inhibitor endostatin in cancer patients in the U.S. Initial laboratory tests were positive; endostatin blocked tumor growth and decreased the incidence of lesions in rats with breast carcinomas. Other studies showed that it blocked tumor growth and increased tumor cell death.